Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options

Biontech

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.

The data showed encouraging anti-tumor responses and a manageable safety profile for pumitamig plus chemotherapy in first-line and second-line treatment settings.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.